Pfizer Seeks U.S. Clearance for Covid Boosters for Older Teens
(Bloomberg) -- Pfizer Inc.'s chief executive said the company has asked the U.S. to allow Covid-19 booster shots for people age 16-17, a move that would expand access to additional doses amid worry about the new omicron virus variant.
Albert Bourla said in a tweet Tuesday that the company asked the Food and Drug Administration for emergency authorization of third doses for the age group. Shares of the drugmaker, which rose 2.5% in regular trading, gained 0.7% after hours in New York.
Currently, people age 5 and older in the U.S. are eligible to receive the messenger RNA vaccine, which Pfizer developed with partner BioNTech SE, but boosters have so far only been cleared for adults.
“It is our hope to provide strong protection for as many people as possible, particularly in light of the new variant,” Bourla said.
The emergence of the omicron strain led U.S. regulators to recommend on Monday that all vaccine recipients 18 and older get a booster six months after receiving a second dose of a messenger RNA vaccine. People who've received the Johnson & Johnson shot can get a booster after two months.
Some researchers have previously expressed concern that younger people, especially young men, could be prone to myocarditis, a heart-related side effect, from additional doses of messenger RNA vaccines. However, Pfizer's shot has been found to be safe and highly effective in clinical trials.
©2021 Bloomberg L.P.
-
Blue Wave Will Derail the AI Trade but Won't Dismantle the AI Era | Unhedged Position
The Democrats' sweep of the US Congress will see politics collide with economic forces both over the long and short term.
-
It's Time To Take The GST Council's Bet On Trust Global
Payment records can prove India's services exports, and clear, proportionate rules can bring foreign digital sellers into the tax net.
-
Opinion | India at 38: From Innovation Overperformer to Innovation Powerhouse
India now has 453 VC-backed deep science startups, 18 of them late-stage, after 117 percent growth since 2020. Laurus Labs, at USD 9.3 billion, is the most valuable deep science company in any middle-income economy outside China.
-
Navigating Energy Crossroads: S Jaishankar's Call For Diversified Supply Chains At G20 Ministerial Meeting
As geopolitical fault lines continue to test maritime trade routes and commodity flows, Jaishankar's message remains pertinent: true economic resilience requires open markets, protected transit lines, and a genuine commitment to multilateral cooperation rather than coercion.
-
Indians Are Travelling, But Not Every Journey Is A Holiday | The Week In Whys
Pilgrims, patients and working women are the real travellers, and the system hasn't quite caught up with them.
-
Getting To Work Costs Women More | The Reason Why
It is not just about women paying more than men. It is about women paying much more in cities than in villages.
-
AI Bias In Investing Cannot Be Eliminated, But It Can Be Governed
Framing is a particularly important example as identical financial information presented in terms of gains rather than losses can lead an LLM to reach a different assessment.
-
Joining The Dots | Dark Skies, Steady Diya: Why Hope Holds This Diwali
With war, a weak rupee and foreign outflows weighing on sentiment, policymakers at the NDTV World Summit and market veterans at NDTV Profit Ignite: Diwali Edition offered the same advice: stay invested and filter out the noise.
-
The Curious Case of Equitas Small Finance Bank And A CEO Who Quit For Stock
PN Vasudevan believes persistent investor concerns over a perceived conflict of interest had become a governance overhang on Equitas Small Finance Bank's stock, even as the lender improved profitability and asset quality.
